Our Anti-Phospholipid IgM and IgG Line Immunoassays were used in two recent studies. These assays are part of our DotDiver line of products from Generic Assays (designed for use with the DotDiver 2.0 Immunoassay Processor).
The first study performed a comparison of the line immunoassays versus the ELISA method to evaluate the sensitivity and specificity. The second study focused on using line immunoassays to examine thrombotic risk of non-criteria anti-phospholipid antibodies. Abstracts and citation information for both studies are below.
Product pages:
DotDiver Anti-Phospholipid IgM
DotDiver Anti-Phospholipid IgG
Contact us for more information about out DotDiver products.
Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. (Full Article)
Abstract Background:
Persistent antiphospholipid antibodies (aPL) constitute the serological hallmark of the anti-phospholipid syndrome (APS). Recently, various new assay technologies for the detection of aPL better suited to multiplex reaction environments than ELISAs emerged. We evaluated the diagnostic performance of such a novel line immunoassay (LIA) for the simultaneous detection of 10 different aPL.
Thaler MA, Bietenbeck A, Steigerwald U, Buttner T, Schierack P, Lindhoff-Last E, et al. (2019) Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. PLoS ONE 14(7): e0220033. https://doi.org/10.1371/journal.pone.0220033
Thrombotic Risk of Non-Criteria Anti-Phospholipid Antibodies Measured by Line Immunoassay: Superiority of Anti-Phosphatidylserine and Anti-Phosphatidic Acid Antibodies (Full Article)
Abstract Background:
Increasing interest has focused on the development of new assays more specific for APS and application of multiple combinations of anti-phospholipid antibodies (aPLs). This study explored the thrombotic risk of non-criteria aPLs measured by a new line immunoassay (LIA) and the benefit of additional non-criteria aPLs results to the APS diagnosis.
Park HS, Gu JY, Jung HS, Kim HK. (2019) Thrombotic risk of non-criteria anti-phospholipid antibodies measured by line immunoassay: superiority of anti-phosphatidylserine and anti-phosphatidic acid antibodies. Clin. Lab. 2019;65:207-213. DOI: 10.7754/Clin.Lab.2018.171207
